Clinical trial NCT06380452: Therapy for Scabies With Two Differently Concentrated Permethrin Creams
Official title: Phase III Multicenter, Prospective, Randomized, Double-blind Study Comparing the Efficacy and Safety of Therapy for Scabies With Two Differently Concentrated Permethrin Creams.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Scabies
Lead sponsor: Infectopharm Arzneimittel GmbH
Sponsor class: INDUSTRY
Collaborators: name: Winicker Norimed GmbH
First posted: 2024-04-23
Enrollment: 220
Sex: ALL
Minimum age (years): 2
Maximum age (years): 85
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The SKABUP study is a prospective, randomized, double-blind, 2-arm superiority study in a group sequential design with recruitment stop and interim analysis after 172 patients. If there is no evidence of superiority in the interim analysis, the study will be continued unchanged up to the planned number of 220 patients and will be terminated and analyzed regularly.
Primary purpose: TREATMENT

Brief summary: The multi-center, prospective, randomized, double-blind phase III clinical trial will primarily investigate the efficacy and safety of treatment of scabies with Permethrin Cream 5% (approved drug InfectoScab 5% Cream) in direct comparison with Permethrin Cream 10%.

The trial participants will be randomly assigned and blinded to either Permethrin Cream 5% or Permethrin Cream 10%.

Detailed description: The SKABUP study is a multi-center, prospective, randomized, double-blind phase III clinical trial. The aim of this SKABUP study is to compare the efficacy and safety of topical therapy with permethrin 5% and permethrin 10% in a multicenter randomized double-blind setting in order to demonstrate the possible superiority of the 10% permethrin cream over the current standard therapy with permethrin 5% cream. In order to demonstrate a possible difference in efficacy as clearly as possible, the study will be conducted in dermatology clinics and without extensive exclusion of previous therapies in the patient's medical history.

The primary objective of the SKABUP study is the clincal efficacy (therapeutic success yes/no) after completion of treatment (one or - if necessary - two applications), i.e. treatment success on day 14 (for study participants with only one application of investigational product) or on day 28 (for study participants with repeated application of investigational product).

A total of 220 scabies patients aged between 2 and 85 years are to be included in the study (clinical trial). After 172 patients, however, recruitment will be stopped and an interim evaluation carried out. If there is proof of superiority, the study will be terminated; if there is no proof of superiority, it will be continued unchanged. Study drop-outs, i.e. patients included in the study with at least one application of an investigational product whose participation in the study ends prematurely, will not be replaced.

Eligibility criteria: Inclusion Criteria:

* Confirmed acute scabies disease: Detection of mites and/or mite nymphs and/or mite larvae, by reflected light microscopy or light microscopy of skin samples, at scabies-typical predilection sites
* Age between 2 years and 85 years
* Written informed consent of the study participant (if of legal age) or all legal guardians (for underage study participants \< 12 years) or all legal guardians and the study participant (for underage study participants ≥ 12 years)
* Practicable application of the trial medication by trained specialist staff at the trial site

Exclusion Criteria:

* Pre-treatment with antiscabiosa in the last 14 days
* Combined antiscabial treatment (i.e. simultaneous/simultaneous topical and systemic scabies treatment with medication) in the last 3 months
* Known intolerance to permethrin, other pyrethroids, chrysanthemums or any of the other ingredients of the study medication
* Scabies crustosa
* Impetiginization/eczematization requiring inpatient treatment
* Body weight \> 120 kg
* Pregnancy, breastfeeding
* Clinically relevant immunodeficiency (of any kind, including extensive local therapy (\>20% body surface) with corticosteroids \> 2 weeks in the last 4 weeks or ≥ 10 mg prednisolone equivalent \>7 days in the last 4 weeks - even without signs of scabies crustosa)
* Other serious illnesses which, in the opinion of the investigator, prevent the patient from participating in the study
* Planned systemic use of corticosteroids
* Planned or previous (last 4 weeks) use of systemic or cutaneous non-steroidal immunosuppressants
* Apparent unreliability or unwillingness to cooperate
* Inability to understand and comply with study instructions
* Known alcohol, medication or drug dependence
* Placement in a facility where people live together for long periods of time, are cared for or receive medical care, and where close skin-to-skin contact is common, or placement in an institution ordered by a court/authority
* 5 or more close contacts (persons with close, extensive skin-to-skin contact with the scabies patient for more than 5-10 minutes)
* Close contact person who refuses scabies treatment or for whom treatment is not possible
* Dependence on sponsor or investigator
* Previous participation in a clinical trial in the last 30 days or in the same clinical trial

Primary outcomes:
measure: clinical efficacy (yes/no)
timeFrame: day 14 - day 28
Secondary outcomes:
measure: effectiveness at Visit 1
timeFrame: day 14
measure: frequency of therapy success
timeFrame: day 0 - day 28
measure: itching
timeFrame: day 0 - day 28
measure: patients with evidence of mites
timeFrame: day 0 - day 28
measure: patients with use of antiscabiosa not compliant with the protocol
timeFrame: day 0 - day 28
measure: patients with new scabies efflorescences
timeFrame: day 0 - day 28
measure: patients with "additional confirmed" treatment failure
timeFrame: day 0 - day 28
measure: AEs, SAEs, ADRs, SUAWs
timeFrame: day 0 - day 28
Other outcomes:
Locations:
Study officials:
affiliation: Universitätsklinik und Poliklinik für Dermatologie une Venerologie, Halle (Saale)
name: Cord Sunderkötter, Prof. Dr.
role: STUDY_DIRECTOR
References: